Activation of antigen-exposed iMC-DCs at the "right place" and "right time" promotes potent anti-tumor immunity

Activation of antigen-exposed iMC-DCs at the "right place" and "right time" promotes potent anti-tumor immunity

To better control the "licensing" of pro-Th1 dendritic cells (DCs), Spencer and colleagues have developed a synthetic ligand-inducible chimeric receptor, iMyD88/CD40 (iMC), incorporating synergistic Toll-like receptor (TLR) and costimulatory signaling elements, permitting DC regulation in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncoimmunology 2012-05, Vol.1 (3), p.362-363
1. Verfasser: Spencer, David M.
Format: Artikel
Sprache:eng
Schlagworte:
Author's View
Binding
Biology
Bioscience
Calcium
Cancer
CD40
Cell
Cycle
dendritic cells
inducible MyD88/CD40 (iMC)
Landes
MyD88
Organogenesis
Proteins
tumor immunotherapy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To better control the "licensing" of pro-Th1 dendritic cells (DCs), Spencer and colleagues have developed a synthetic ligand-inducible chimeric receptor, iMyD88/CD40 (iMC), incorporating synergistic Toll-like receptor (TLR) and costimulatory signaling elements, permitting DC regulation in vivo within the context of an immunological synapse. This novel technology results in potent anti-cancer activity.
ISSN:2162-4011
2162-402X
2162-402X
DOI:10.4161/onci.18482